# EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC

Source: https://onco.cc/trials/nct07617805/  
OnCo record `nct07617805` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of therascreen companion diagnostic kits, Fludarabine, Cyclophosphamide in head and neck squamous cell carcinoma, run by Beijing Biotech, now recruiting.

## Summary

EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC is a phase 1/2 interventional study registered as NCT07617805 by Beijing Biotech, with 42 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-03-14. Interventions recorded: EGFR/HER2 Dual-Target CAR-NK Cells, Fludarabine, Cyclophosphamide. Conditions listed: Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Biomarker-positive EGFR/HER2- Expressing HNSCC. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07617805
- Phase: 1/2
- Setting: A Phase 1/2, Open-Label, Biomarker-Enriched Study of Allogeneic EGFR/HER2 Dual-Target CAR-NK Cells Following Fludarabine/Cyclophosphamide Lymphodepletion in Adults With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Sponsor: Beijing Biotech
- Enrolled: 42

## Sources

- ClinicalTrials.gov NCT07617805: https://clinicaltrials.gov/study/NCT07617805

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Fludarabine](https://onco.cc/drugs/fludarabine/), [therascreen companion diagnostic kits (KRAS, EGFR, PIK3CA, FGFR, BRAF)](https://onco.cc/drugs/therascreen-cdx/)

---
JSON: https://onco.cc/api/v1/entities/nct07617805.json